A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Authors:
Open Access
- 7 July 2022
- journal article
- research article
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 29 (1) , 1-13
Abstract
Background: With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efficacy. Methods: We report an mRNA-based vaccine using an engineered “hybrid” receptor binding domain (RBD) that contains all 16 point-mutations shown in the currently prevailing Omicron and Delta variants. Results: A booster dose of hybrid vaccine in mice previously immunized with wild-type RBD vaccine induced high titers of broadly neutralizing antibodies against all tested SARS-CoV-2 variants of concern (VOCs). In naïve mice, hybrid vaccine generated strong Omicron-specific neutralizing antibodies as well as low but significant titers against other VOCs. Hybrid vaccine also elicited CD8+/IFN-γ+ T cell responses against a conserved T cell epitope present in wild type and all VOCs. Conclusions: These results demonstrate that inclusion of different antigenic mutations from various SARS-CoV-2 variants is a feasible approach to develop cross-protective vaccines.Keywords
All Related Versions
Funding Information
- Institute of Biomedical Sciences, Academia Sinica (AS-KPQ-110-EIMD, AS-KPQ-111-KNT)
This publication has 43 references indexed in Scilit:
- Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort studyThe Lancet Infectious Diseases, 2022
- SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasionNature, 2021
- Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19PLOS Pathogens, 2021
- SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responsesNature, 2021
- SARS-CoV-2 variants, spike mutations and immune escapeNature Reviews Microbiology, 2021
- SARS-CoV-2 VaccinesJAMA, 2021
- Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesNature Medicine, 2021
- Maturation and persistence of the anti-SARS-CoV-2 memory B cell responseCell, 2021
- Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike proteinVaccine, 2020
- A Thermostable mRNA Vaccine against COVID-19Cell, 2020